Jin Li

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 22

Top Venues

Nature medicine

Journal of cancer research and clinical oncology

Cancer communications (London, England)

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine 30 (3) (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine 30 (3) (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine 30 (3) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Weijian Zhou, Gaoshaer Yeerkenbieke, Yumei Zhang, Mingwang Zhou, Jin Li
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Journal of cancer research and clinical oncology 150 (2) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine 30 (3) (2024)
Feng-Hua Wang, Lin Shen, Weijian Guo, Tian-Shu Liu, Jin Li, Shukui Qin, Yuxian Bai, Zhendong Chen, Jufeng Wang, Yue-Yin Pan, Yongqian Shu, Fuyou Zhao, Ying Cheng, Feng Ye, Kangsheng Gu, Tao Zhang, Hongming Pan, Haijun Zhong, Fuxiang Zhou, Yanru Qin, Lei Yang, Weidong Mao, Qiu Li, Wenxiang Dai, Wei Li, Shubin Wang, Yong Tang, Dong Ma, Xianli Yin, Yanhong Deng, Ying Yuan, Man Li, Wenwei Hu, Donghui Chen, Guoxin Li, Qiqi Liu, Panfeng Tan, Songhua Fan, Michael Shi, Weiguo Su, Rui-Hua Xu
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nature medicine 30 (8) (2024)
Jin Li, Zhendong Chen, Yuxian Bai, Bo Liu, Qingshan Li, Jingdong Zhang, Jun Zhou, Ting Deng, Fuyou Zhou, Shegan Gao, Shujun Yang, Feng Ye, Long Chen, Wei Bai, Xianli Yin, Shundong Cang, Lianke Liu, Yueyin Pan, Hui Luo, Yanxia Ji, Zhen Zhang, Jufeng Wang, Quanliang Yang, Na Li, Rong Huang, Chenglin Qu, Jing Ni, Bo Wang, Yan Xu, Jin Hu, Qingmei Shi, Jason Yang
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nature medicine (2024)
Shu-Kui Qin, Tian-Shu Liu, Jian-Ming Xu, Qi Li, Ying Cheng, Aimar Zhang, Regina Esser, Helena Chang, Jin Li
Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer. Future oncology (London, England) (2023)
Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, Kehe Chen, Peiguo Cao, Jianjun Xiao, Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Lin Han, Qingyu Wang, Jun Zhu, null null
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. British journal of cancer 127 (12) (2022)

Jin Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jin Li